Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Director departure
|
ABEONA THERAPEUTICS INC. (ABEO)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/08/2023 |
8-K
| Quarterly results |
07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
07/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT Abeona Therapeutics Inc. Warrant Shares : ______________ Issue Date: July ___ , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, [●] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meani...",
"Tel: 212 728 8000 Fax: 212 728 8111",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 3, 2023, between Abeona Therapeutics Inc., a Delaware corporation , and the purchasers identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended and the rules and regulations of the Securities and Exchange Commission thereunder, the Company desires to issue and sell to the several Purchasers, and the several Purchasers desire to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration t...",
"Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules" |
|
05/17/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/11/2023 |
8-K
| Quarterly results |
03/29/2023 |
8-K
| Quarterly results |
03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
11/14/2022 |
8-K
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
08/17/2022 |
8-K
| Quarterly results |
08/11/2022 |
8-K
| Quarterly results |
07/20/2022 |
8-K
| Quarterly results |
06/30/2022 |
8-K
| Quarterly results |
06/14/2022 |
8-K
| Quarterly results |
05/19/2022 |
8-K
| Quarterly results |
05/17/2022 |
8-K
| Quarterly results |
05/13/2022 |
8-K
| Quarterly results |
05/02/2022 |
8-K
| Quarterly results |
04/29/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
03/31/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
03/09/2022 |
8-K
| Quarterly results |
12/17/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"UNDERWRITING AGREEMENT",
"COMMON STOCK PURCHASE WARRANT Abeona Therapeutics Inc. Warrant Shares: _______ Initial Exercise Date: December 21, 2021 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on December 21, 2026 but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in the form of a security held in book-entry form ...",
"1330 Avenue of the Americas, 33rd Floor",
"Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants" |
|
12/16/2021 |
8-K
| Quarterly results |
11/19/2021 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs:
|
"AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENT This Amendment No. 1 amends that certain Open Market Sale Agreement, dated as of August 17, 2018 , by and between Abeona Therapeutics Inc. and Jefferies LLC . Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement. WITNESSETH THAT: WHEREAS, Section 17 of the Agreement permits the Company and the Agent to amend the Agreement; WHEREAS, the Company reaffirms and restates all of the representations and warranties of the Company included in the Agreement as of the date hereof; and WHEREAS, the Company and the Agent now desire to amend the Agreement as provided herein. NOW, THEREFORE, in consideration of the premises the Company and the Agent agree as follows: 1. The second paragraph of Sect...",
"1330 Avenue of the Americas, 33rd Floor" |
|
11/15/2021 |
8-K
| Quarterly results |
11/15/2021 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
09/21/2021 |
8-K
| Quarterly results |
08/13/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
07/28/2021 |
8-K
| Quarterly results |
07/16/2021 |
8-K
| Other Events Interactive Data |
05/28/2021 |
8-K
| Quarterly results |
05/26/2021 |
8-K
| Quarterly results |
05/18/2021 |
8-K
| Quarterly results |
|
|
|